Introduction
Primary graft dysfunction (PGD) is a common complication of lung transplantation, affecting an estimated 10-25% of postoperative lung transplantation patients [1] [2] [3] [4] [5] . It is the leading cause of early posttransplantation morbidity and mortality [1, [5] [6] [7] . Given the overall importance of PGD to advancing the field of lung transplantation, the International Society for Heart and Lung Transplantation (ISHLT) formed the Working Group on Primary Graft Dysfunction. In 2005, this group provided a comprehensive series of publications summarizing the current understanding of PGD, as well as suggesting standardized criteria for defining PGD [6, [8] [9] [10] [11] [12] .
The ISHLT Working Group adopted the name 'primary graft dysfunction' for the syndrome and standardized a grading schema that contains a severity grade based on arterial oxygen tension/fractional inspired oxygen and the presence or absence of chest radiograph infiltrates (Table 1) [9] . Time points at which to apply the grading were recommended to serve as a guide for describing patterns of PGD, and to suit different clinical and research purposes: T0 (within 6 h of final lung reperfusion), T24, T48, and T72. These criteria represent the initial steps in standardizing the definition for both clinical and research purposes, and, as such, the definition should be viewed as a work in progress. Different 'flavors' of PGD may have different clinical impacts. For example, more stringent definitions of PGD, such as those most similar to acute respiratory distress syndrome (ARDS), may be useful as outcomes in studies aimed at investigating the risks or mechanisms of lung injury, whereas lesser degrees of lung injury at earlier stages may be important for studying the impact of postoperative lung injury on longer-term outcomes, such as bronchiolitis obliterans syndrome (BOS). Furthermore, the application of the criteria may vary according to clinical parameters, such as diagnosis or transplant type [13 ] .
Incidence and outcomes of primary graft dysfunction
Most studies of the incidence and outcomes of PGD were published before the standardization of PGD defining criteria, and the differences in definition are evident in inconsistencies both in the reported incidences of PGD as well as the reported associations of PGD with mortality [6] . Authors who employed definitions of PGD similar to the definition of ARDS (grade 3 PGD) reported an incidence of PGD between 10 and 25%, with 30-day mortality of approximately 50% among those with PGD compared with less than 10% without PGD [1] [2] [3] 5, 14] . In contrast, authors who defined PGD at earlier time points or employed less stringent thresholds for oxygen requirement have shown incidences between 50 and 57% and no significant mortality differences [15, 16] . Database studies of PGD are hampered by the lack of clear defining criteria employed consistently across centers; there is no standard definition of PGD in the ISHLT registry beyond a single field for 'prolonged graft dysfunction during initial hospitalization'. Despite this situation, PGD defined in this way reveals a similarly high mortality (42%) when compared with single-center studies employing rigid definitions of PGD [7] . More recently, a modified ISHLT PGD grading system was assessed, and the authors illustrated a similarly large impact on PGD outcomes. Subjects with grade 3 PGD had a 90-day mortality of 33%, significantly longer intensive care unit and hospital stays, and significantly decreased long-term survival than those with grades 1 and 2 [17 ] .
In addition to the clear impact on early mortality, survivors of PGD have been shown to have substantial functional impairments 12 months after transplant [7] , as well as increased long-term mortality compared with those with no PGD [5] . Conditional on 12-month survival, subjects who had PGD were approximately 33% more likely to die over the next 4 years than those without PGD [5] . The reasons for this differential survival are not known; however, recent research suggests that survivors of PGD have an increased risk of developing BOS [18 ] . In a cohort study of 334 lung transplant recipients, all PGD grades (classified according to ISHLT guidelines) were associated with a significantly increased risk of stage 1 BOS that, in multivariable modeling, was independent of acute rejection, lymphocytic bronchitis, and community acquired respiratory viral infections [18 ] . These findings suggest that even mild or early forms of lung injury have a significant impact on the risk of BOS.
Pathophysiology
PGD is a consequence of the sequence of events inherent in the lung transplantation process, beginning with the brain death of the donor, pulmonary ischemia, and preservation of donor tissue, transplantation, and reperfusion of donor tissue in the recipient. Many different mechanisms contribute to lung injury from PGD. Early injury may be largely initiated by reactive oxygen species generated during ischemia and reperfusion. During cold ischemic storage of the lung allograft, hypoxia can lead to adenosine triphosphate depletion and hypoxanthine generation, which generates superoxide through xanthine oxidase during reperfusion/reoxygenation. The highly reactive superoxide may also be generated through nicotinamide adenine dinucleotide phosphate, reduced form, oxidase [19] [20] [21] , present on polymorphonuclear cells [22] [23] [24] , or the pulmonary endothelium [19, 25] .
In addition to oxidant stress mechanisms, during this process there is an increased production/presence of adhesion molecules on pulmonary cells and macrophages. As a result, proinflammatory cytokines are released, activating recipient neutrophils and T lymphocytes [26] . In response to cellular injury, platelet activating factor is released, inducing platelet activating factor receptors, which activate leukocytes and stimulate platelet aggregation, cytokine release, and the expression of cell adhesion molecules [27, 28] . After reperfusion, activation of the complement system may further enhance lung injury via increased smooth muscle contraction, upregulation of vascular permeability, and the release of cytotoxic granules from various immune cells [29] . Furthermore, increased levels of endothelins, which are powerful vasoconstrictors, may also augment lung injury by stimulating macrophages to produce cytokines and increase the concentration of neutrophils in the lung [30] .
There is evidence that macrophages, lymphocytes, and neutrophils all play a role in PGD pathogenesis. Before and after reperfusion, because of the release of cytokines and other mediators, the transplanted lung is scouted by and filled with lymphocytes and neutrophils [31] . In response to the oxidative stress that occurs, cytokines and procoagulant agents are activated by alveolar macrophages [32, 33] . After reperfusion, lymphocytes also play an active roll in lung injury by releasing interferon gamma [34] .
Clinical risk factors for primary graft dysfunction
Risk factors for PGD can be thought of as related to the donor, recipient, or procedure. Clinical donor and recipient-related risk factors are presented in Table 2 . 
Donor-related risk factors
In general, donor-related risk factors may be categorized as inherent lung donor characteristics, acquired lung donor characteristics, and factors related to the methods of donor lung procurement, preservation, and storage.
Inherent lung donor characteristics studied for their relationship with PGD include donor age, sex, race and smoking status. Older donor age has been associated with PGD, with an increased risk occurring in donors more than 32-45 years [3, 35, 36] . These findings are consistent with the effects of donor age seen in other organs; however, advanced age should not limit the use of such lungs if other risk factors are not present [10] . The association of younger donor age (< 21 years) has been less consistent, as has donor female sex [3, 10] . Although the donor's race and sex may affect the risk of PGD development [3] , mechanisms underlying these differences remain speculative, and consensus advises against considering these factors when determining the acceptability of a donor lung [10] . The impact of donor smoking on PGD development is controversial [3, 35, 37, 38] , and should be studied in larger groups of patients.
Acquired lung donor risk factors for PGD are those that affect the donor lung immediately pre-or postdonor brain death, and include: the occurrence of brain death; prolonged mechanical ventilation; bronchoaspiration; pneumonia; trauma; multiple blood transfusions; and hemodynamic instability [10] . Traditional assessments of donor lungs, including donor history, arterial blood gases, chest X-ray appearance, bronchoscopy findings, and physical examination, have not proved accurate for predicting the development of PGD. Alternative methods of donor assessment are emerging, including the sampling of pulmonary venous blood [39] .
Recipient-related risk factors
Methodological issues have significantly hampered early studies of recipient-related risk factors for PGD. As a result, there is insufficient evidence to make conclusive associations between PGD and many potential risk factors, including: advanced or young age; race; sex; previous chest surgery; liver dysfunction; renal dysfunction; left heart disease; blood transfusion; and single versus bilateral transplantation [11] . Consistent associations have, however, been found between the recipient's pretransplant diagnosis and the risk of the subsequent development of PGD. A diagnosis of primary pulmonary hypertension is a risk factor for the development of PGD [3, 35] . Associations between secondary pulmonary hypertension and PGD development are less conclusive [11] . The relationship between the use of cardiopulmonary bypass and PGD is difficult to assess as a result of confounding by pulmonary hypertension.
Prevention and management of primary graft dysfunction
Controlled human studies of PGD prevention and management have been sparse to date. Nonetheless, knowledge gained in basic studies has contributed to advances in the field and will continue to do so in the future.
Prevention
Over a decade of research has led to lung preservation techniques that reduce ischemia-reperfusion injury. These preservation techniques may be applied during lung procurement, perfusion of preservation solution, and storage en route to transplantation. Preservation protocols vary between institutions, but generally include ventilation during lung procurement, controlled flush of a volume of hypothermic preservation solution into the pulmonary arteries (some institutions also flush preservation solution in a retrograde fashion via the pulmonary veins), inflation of the lung to a specified volume or airway pressure for storage (with lower-range fractional inspired oxygen), and storage of the lung in hypothermia for transport. With these advances, ischemic times of 6-8 h have generally become acceptable [10] .
Human studies of PGD prevention are sparse. The bestperformed study of PGD prevention revealed that there was no beneficial effect of nitric oxide therapy on PGD incidence [40] . A second, smaller study revealed that TP-10, a soluble complement receptor 1 inhibitor, reduced the length of mechanical ventilation, but had insufficient power to detect differences in PGD Primary graft dysfunction Hoffman et al. 475 incidence [41] . More recent observational research has addressed preservation solutions, building from contemporary thought that extracellular-type preservation solutions (low potassium) are associated with a decreased incidence of PGD [42] . Although preservation solution studies have used historical controls and thus compare patients of different eras, they support the notion that the use of Perfadex is associated with a lower incidence of PGD [43, 44] .
In addition, PGD prevention therapies aimed at the donor are emerging. Such interventions are summarized in Table 3 and include: steroids to reduce lung inflammation after brain death; the vasopressors dopamine and vasopressin to reduce hypotension and hemodynamic instability after brain death; antibiotic treatment to reduce the incidence of pneumonia; and bronchoalveolar lavage (BAL) of donor lung to tailor postoperative antibiotic therapy [10] . Studies of these agents to date have been small, and larger clinical studies are needed before recommending routine use for PGD prevention; however, these agents remain at the clinician's discretion for the management of brain death.
Management
PGD management strategies are summarized in Table 4 , and have recently been reviewed [12] . In general, the principles of management are similar to those for ARDS, as the two syndromes share characteristic clinical findings and pathophysiology. No PGD management strategies have been subjected to clinical trials. The overall strategy is supportive, minimizing secondary organ damage while allowing time for PGD-related lung injury to regress. Generally accepted therapies include lung protective mechanical ventilation, conservative crystalloid fluid management, and optimization of hematocrit (to range 25-30%) and coagulation parameters. The use of nitric oxide for selected patients with severe hypoxemia or pulmonary hypertension is justified, although it has not been proved useful for prevention. Low-dose prostaglandin E 1 likewise may be helpful, although this compound has not been studied. For life-threatening PGD not responding to other supportive therapy within the first 7 days posttransplant, extracorporeal life support measures should be considered. Re-transplantation should also be considered in patients without other end-organ failure, although the outcomes of patients re-transplanted for PGD are significantly worse than other indications [12] .
Molecular markers
In general, studies of molecular markers for PGD prediction are in the early stages. Although utility in prediction will require future validation studies, some interesting insights into the potential pathophysiology of PGD have been obtained from human studies. Elevated IL-8 levels in BAL and lung tissues of brain-dead donors have been associated with the incidence of PGD [31, 45] . IL-6/IL-10 messenger RNA ratios have predicted mortality from PGD [46] .
Two prospective cohort studies have recently implicated endothelial-related mechanisms. Preoperative serum concentrations of vascular endothelial growth factor, the major mediator of ischemia-reperfusion-induced vascular permeability [47] , were significantly higher in subjects who eventually developed grade 3 PGD [48 ] . A second study showed that lower protein C and higher type 1 plasminogen activator inhibitor (PAI-1) levels over the course of the 72-h period after transplantation are associated with PGD. PAI-1 levels were associated with higher recipient pulmonary artery pressures, and thus may link pulmonary hypertension to the development of PGD [49 ] .
Experimental approaches to primary graft dysfunction prevention or therapy
Innovative interventions are being studied in the laboratory as potential PGD risk reduction strategies (Table 3) .
In rat transplantation models, preharvest donor inhalation 476 Lung transplantation of carbon monoxide inhibited proinflammatory and prothrombotic mediators in the lung posttransplantation [50 ] , and improved graft function via the prevention of ischemia-reperfusion injury [51 ] . Intravenous pretreatment of rats before ischemia-reperfusion injury with mycophenolate mofetil resulted in reduced lung vascular permeability indices and reduced markers of lung inflammation [52] . Hypertensive crisis during donor brain death may need to be more aggressively addressed. Lungs from rats pretreated with a-adrenergic blockade before imposed brain death had less evidence of reperfusion injury after transplantation than lungs from nonpretreated rats [53 ] . Indoleamine 2,3-dioxygenase (IDO) is a catalyst of oxidative cleavage in a pathway leading to T-cell suppression, produces radical scavengers, and may mediate multiple mechanisms responsible for PGD. Rats receiving donor lungs with genetically induced overexpression of IDO have reduced evidence of ischemia-reperfusion injury [54 ] . Inhalation of the b 2 -adrenoreceptor agonist salmeterol xinafoate during 55 min of warm ischemia reduced markers of ischemiareperfusion injury in an isolated rat lung-perfusion model [55 ] . In addition to these therapies, forthcoming studies of b-agonists for lung injury may prove treatment benefit [55 ] . It is hoped that these laboratory-based discoveries can be translated into clinical interventions in the future.
Emerging research is challenging the notion that lungs from non-heart-beating donors are unsuitable because of a high risk of PGD. In a mouse model, significant increases in BAL macrophages and lymphocytes were not seen until after 60 min of warm ischemic time [56 ] . Lungs from non-heart-beating donor pigs showed less clinical evidence of reperfusion injury than lungs retrieved 5 h after brain death from heart-beating pigs [57 ] .
Conclusion
PGD is a common development after lung transplantation, and is a major cause of morbidity and mortality. Recent standardization of the defining criteria for PGD should help spur additional clinical and translational research in humans. Many PGD-related interventions on the horizon hold promise to improve outcomes significantly after lung transplantation.
